<DOC>
	<DOCNO>NCT00107783</DOCNO>
	<brief_summary>This 3-year study examine safety effectiveness long-term use nitisinone ( Orfadin ) treat joint problem patient alkaptonuria , inherited disease compound call homogentisic acid accumulates . The excess homogentisic acid cause arthritis limited joint movement . It also cause heart valve damage kidney stone . Patients 30 80 year age alkaptonuria may eligible study . Patients must hip involvement , least one remain hip joint . Candidates recruit among patient enrol protocol 00-HG-0141 , `` Clinical , Biochemical , Molecular Investigations Alkaptonuria . '' Participants may enter protocol simultaneously . Participants randomly assign one two treatment group : one group take regular medicine plus 2-mg nitisinone capsule daily ; group take regular medicine . Patients take nitisinone blood test measure liver function 2 week 6 week start treatment . Before start therapy , patient admit NIH Clinical Center 4-5 day undergo follow procedure : - Medical history physical examination - 24-hour urine collection test sugar , protein , molecules - Blood test liver thyroid function , blood count , blood chemistry - Blood urine test measure tyrosine amino acid homogentisic acid - Bone x-rays - Spiral CT ( compute tomography ) abdomen detect kidney stone - Eye examination evaluation specialist rehabilitation medicine pain , plus consults skin , brain , lung , heart , kidney , need All patient , whether receive nitisinone , return Clinical Center 2-3 day follow-up admission every 4 month history physical examination , blood test , two 24-hour urine collection . Every 12 month ( 12 , 24 36 month start study ) , patient also repeat bone x-ray , spiral CT , kidney ultrasound , echocardiogram , electrocardiogram . An MRI brain do end study . Sixteen month end study enrollment period , treat non-treated group evaluate . If nitisinone delay progression joint disease treat group , study continue patient receive drug remainder study . If , study continue another 20 month , time study end evaluation process repeat . Patients develop symptom corneal crystal , pain , severe liver nervous system toxicity may take study .</brief_summary>
	<brief_title>Long-Term Study Nitisinone Treat Alkaptonuria</brief_title>
	<detailed_description>Alkaptonuria rare metabolic disease homogentisic acid ( HGA ) , intermediary metabolite tyrosine catabolism , accumulates due deficiency enzyme homogentisic acid oxidase . Patients alkaptonuria exhibit homogentisic aciduria ochronosis , dark pigmentation various tissue due bind HGA oxidized metabolite . The ochronosis result debilitate destruction cartilage , arthritis , lumbosacral ankylosis , limitation motion , bone deterioration later life . No effective therapy exist alkaptonuria . However , compound name 2- ( 2-nitro-4-trifluoromethylbenzoyl ) - 1 , 3-cyclohexanedione ( nitisinone , NTBC , Orfadin ) inhibit 4-hydroxyphenylpyruvate dioxygenase , enzyme produce HGA . Nitisinone , dose approximately 1 mg/kg/day , proven safe effective tyrosinemia type I , cause fatal liver disease infant child . Under protocol 97-HG-0201 , treat 9 alkaptonuria patient nitisinone ; 7 receive 1.05 mg twice daily , HA fell 4.0 plus minus 1.8 g/24h 0.2 plus minus 0.2 g/24h ( normal 0.028 plus minus 0.015 g/24h , n=10 ) . Plasma tyrosine level rise 67 plus minus 18 micro M 760 plus minus 181 micro M. The current protocol ( 05-HG-0076 ) randomize , control clinical trial determine nitisinone ( 2 mg daily ) beneficial joint symptom alkaptonuira . Patients examine NIH Clinical Research Center every 4 month 3 year . Hip joint range motion serve primary outcome parameter , nitisinone ( Orfadin ) provide Swedish Orphan International IND obtain William A. Gahl . Forty patient ( 20 nitisinone treatment 20 untreated ) enrol least 16 month , interim analysis show promise result . Serious adverse event patient nitisinone include death myocardial infarction , keratopathy , elevate liver function test related gallstone .</detailed_description>
	<mesh_term>Alkaptonuria</mesh_term>
	<mesh_term>Ochronosis</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 3080 year , either gender Diagnosis alkaptonuria base upon urinary HGA excretion great 0.4 g/24h At least one hip joint remain Some evidence hip involvement , e.g. , pain decrease range motion Ability travel NIH Clinical Research Center admissions Ability consent Availability local medical followup EXCLUSION CRITERIA : Age le 30 great 80 Nonalkaptonuria cause ochronosis Bilateral hip joint replacement Keratopathy Contact lenses Uncontrolled glaucoma History myocardial infarction History emphysema pulmonary insufficiency ( Forced vital capacity le 70 % ) Psychiatric illness neurological disease interfere compliance communication health care personnel Current malignancy Open skin lesion Dietary habit use homeopathic therapy interfere tyrosine catabolism . The diet must reasonably balance , determined dietician . Uncontrolled hypertension ( blood pressure great 180 systolic great 95 diastolic ) History extreme alcohol abuse sever liver disease Liver great 3 cm right costal margin Electrocardiogram change indicative myocardial infarction , arrhythmia , tachycardia , bradycardia , leave bundle branch block Chest radiographic abnormality , include infiltrate , mass , congestive heart failure , embolism , atelectasis Serum postassium less 3 . 0 mEq/L Serum creatinine great 2.0 mg/dL SGPT great 41 U/L SGOT great 34 U/L CK great 500 U/L Hemoglobin le 10.0 g/dL Platelets le 100 k/mm ( 3 ) WBC le 3.0 k/microL T4 great 15 microg/dL T4 le 4 microg/dL ESR great 100 mm/h Plasma tyrosine great 150 microM</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Homogentisic Acid</keyword>
	<keyword>Corneal Damage</keyword>
	<keyword>Tyrosine</keyword>
	<keyword>Alkaptonuria</keyword>
	<keyword>Photophobia</keyword>
	<keyword>Nitisinone</keyword>
</DOC>